News

Genomic assays play a critical role in guiding treatment decisions for patients with early-stage invasive breast cancer by providing prognostic and predictive insights. In a live Community Case Forum ...
Discover which therapies are expected to grab the HER2-low cancers market share @ HER2-low Cancers Market Report The HER2-low ...
In this video, Megan Kruse, MD, breast medical oncologist at Cleveland Clinic, discusses results from an interim analysis of the DESTINY-Breast09 trial, which were presented at ASCO Annual Meeting.The ...
Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus ...
The partners have committed to awarding two grants, totaling around $2.3 million, to researchers studying this lung cancer subset.
During a live event, Hari Deshpande, MD, and participants discussed the DeFi trial and the management of nirogacestat in ...
AstraZeneca, Pfizer and more are leveraging the computational power of AI to better design trials, predict the potential ...
New data shed light on the best strategies for managing patients who develop interstitial lung disease while being treated ...
Researchers evaluated current treatment patterns and clinical outcomes for patients with HER2-positive metastatic breast cancer.
Novellia, Inc., the AI health data platform trusted by leading biopharma companies to uncover hidden insights in real-world patient data, today announced that its CEO and co-founder Shashi Shankar has ...
T-DXd plus pertuzumab can improve outcomes when compared to treatment with a taxane, trastuzumab, and pertuzumab in patients with HER2+ advanced breast cancer.
Download to gain expert insights and data-driven analysis from the ASCO 2025 Annual Meeting. This report covers key ...